Afrezza Just Entered the Pediatric Diabetes Market-Can This First-Mover Win Reprice MannKind?

FDA approval gives Afrezza a first-mover position in pediatric diabetes

MannKind's story changed with the FDA's approval of Afrezza for children and adolescents aged 6 and older with type 1 and type 2 diabetes, making it the first and only inhaled mealtime insulin approved for pediatric type 1 diabetes. The opportunity is meaningful because more than 350,000 children and adolescents live with diabetes in the U.S.